Wall Street projections for Hims stock forecast 2030 anchor on the expansion of OTC and prescription product pipelines. A diversified revenue mix strengthens resistance to sector volatility. “The termination of this partnership suggests that Novo still views Hims’ marketing and sales tactics as a threat to branded Wegovy and indicates Novo considers Hims more of a competitor than a true partner,” Aaron DeGagne, a senior analyst of healthcare at PitchBook, said in a statement. 5 Hot Stocks to Buy Now: October's Top Picks With Major Upside Quantitative models for Hims stock forecast 2030 apply discounted cash flow analysis, indicating intrinsic value could exceed current market price by 35% given sustained operational scaling.